Community Pharmacist Targeted Screening for Chronic Kidney Disease

Overview

Journal Can Pharm J (Ott)

Specialty Pharmacology

Date 2016 Jan 23

PMID 26798373

Citations 14

Authors

Yazid N Al Hamarneh

Brenda Hemmelgarn

Craig Curtis

Carlee Balint

Charlotte A Jones

Ross T Tsuyuki

Affiliations

Soon will be listed here.

Citing Articles

[Screening for Chronic Kidney Disease in the Community Pharmacy. CRIERFAC Study: Description of the Methodology].

Salar Ibanez L, Espejo Guerrero J, Satue E, Perez Leon N, Martinez-Berganza Asensio M Farm Comunitarios. 2024; 16(2):5-13.

PMID: 39156030 PMC: 11328524. DOI: 10.33620/FC.2173-9218.(2024).12.

Community pharmacist-led point-of-care eGFR screening: early detection of chronic kidney disease in high-risk patients.

Jairoun A, Al-Hemyari S, Shahwan M, Zyoud S, El-Dahiyat F Sci Rep. 2024; 14(1):7284.

PMID: 38538618 PMC: 10973329. DOI: 10.1038/s41598-024-56765-0.

Optimizing Collaborative Care of Patients with Chronic Kidney Disease Associated with Type 2 Diabetes: An Example Practice Model at a Health Care Practice in Kentucky, United States.

Gatlin B, Miller J, Chang S Diabetes Ther. 2023; 15(1):1-11.

PMID: 37914833 PMC: 10786800. DOI: 10.1007/s13300-023-01500-7.

"Why Didn't They Teach Us This?" A Qualitative Investigation of Pharmacist Stakeholder Perspectives of Business Management for Community Pharmacists.

Davey B, Lindsay D, Cousins J, Glass B Pharmacy (Basel). 2023; 11(3).

PMID: 37368425 PMC: 10301074. DOI: 10.3390/pharmacy11030098.

Optimizing Multidisciplinary Care of Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus.

Kelepouris E, St Peter W, Neumiller J, Wright E Diabetes Ther. 2023; 14(7):1111-1136.

PMID: 37209236 PMC: 10241769. DOI: 10.1007/s13300-023-01416-2.

References

Szczech L, Stewart R, Su H, DeLoskey R, Astor B, Fox C . Primary care detection of chronic kidney disease in adults with type-2 diabetes: the ADD-CKD Study (awareness, detection and drug therapy in type 2 diabetes and chronic kidney disease). PLoS One. 2014; 9(11):e110535. PMC: 4245114. DOI: 10.1371/journal.pone.0110535. View

Tobe S, Stone J, Brouwers M, Bhattacharyya O, Walker K, Dawes M . Harmonization of guidelines for the prevention and treatment of cardiovascular disease: the C-CHANGE Initiative. CMAJ. 2011; 183(15):E1135-50. PMC: 3193113. DOI: 10.1503/cmaj.101508. View

Cheng A . Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada. Introduction. Can J Diabetes. 2013; 37 Suppl 1:S1-3. DOI: 10.1016/j.jcjd.2013.01.009. View

Tanguay J, Bell A, Ackman M, Bauer R, Cartier R, Chan W . Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy. Can J Cardiol. 2013; 29(11):1334-45. DOI: 10.1016/j.cjca.2013.07.001. View

Jafar T, Schmid C, Landa M, Giatras I, Toto R, Remuzzi G . Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med. 2001; 135(2):73-87. DOI: 10.7326/0003-4819-135-2-200107170-00007. View

Mitra P, Bradley J . Chronic kidney disease in primary care. J R Soc Med. 2007; 100(1):40-5. PMC: 1761681. DOI: 10.1177/014107680710000115. View

Curtis C, Balint C, Al Hamarneh Y, Donald M, Tsuyuki R, McBrien K . Online clinical pathway for managing adults with chronic kidney disease. Can Pharm J (Ott). 2015; 148(5):257-62. PMC: 4561460. DOI: 10.1177/1715163515597243. View

Hackam D, Quinn R, Ravani P, Rabi D, Dasgupta K, Daskalopoulou S . The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol. 2013; 29(5):528-42. DOI: 10.1016/j.cjca.2013.01.005. View

Arora P, Vasa P, Brenner D, Iglar K, McFarlane P, Morrison H . Prevalence estimates of chronic kidney disease in Canada: results of a nationally representative survey. CMAJ. 2013; 185(9):E417-23. PMC: 3680588. DOI: 10.1503/cmaj.120833. View

10.

Tam-Tham H, Clement F, Hemmelgarn B, Manns B, Klarenbach S, Tonelli M . A Cost Analysis and Cost-Utility Analysis of a Community Pharmacist-Led Intervention on Reducing Cardiovascular Risk: The Alberta Vascular Risk Reduction Community Pharmacy Project (REACH). Value Health. 2019; 22(10):1128-1136. DOI: 10.1016/j.jval.2019.05.012. View

11.

Lewis E, Hunsicker L, Clarke W, Berl T, Pohl M, Lewis J . Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001; 345(12):851-60. DOI: 10.1056/NEJMoa011303. View

12.

Anderson T, Gregoire J, Hegele R, Couture P, Mancini G, McPherson R . 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2013; 29(2):151-67. DOI: 10.1016/j.cjca.2012.11.032. View

13.

Zillich A, Saseen J, DeHart R, Dumo P, Grabe D, Gilmartin C . Caring for patients with chronic kidney disease: a joint opinion of the ambulatory care and the nephrology practice and research networks of the American College of Clinical Pharmacy. Pharmacotherapy. 2005; 25(1):123-43. DOI: 10.1592/phco.25.1.123.55628. View

14.

Wright Jr J, Bakris G, Greene T, Agodoa L, Appel L, Charleston J . Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002; 288(19):2421-31. DOI: 10.1001/jama.288.19.2421. View